Allon Therapeutics confirms oral bioavailability of AL-309

---

Allon Therapeutics Inc. releases new data confirming that the company's product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information serves to confirm the potential of AL-309 as a highly novel central nervous system drug.

"These new results are quite significant as they show that AL-309 passes through two meaningful barriers to drug delivery: the intestinal wall and the blood-brain barrier (BBB)," said Gordon McCauley, president of CEO of Allon. "These characteristics are essential for an orally administered central nervous system drug and validate the company's program to develop AL-309 as a treatment for neurodegenerative disease."

McCauley said AL-309 will be the first product to move into clinical development from the company's second platform of neuroprotective compounds. AL-309 will complement development of AL-108 and AL-208, which are currently being evaluated in Phase II clinical trials as treatments for Alzheimer's disease and for mild cognitive impairment associated with coronary bypass graft surgery. A third Phase II trial will begin in mid-2007 to evaluate AL-108 as a treatment for schizophrenia-related cognitive impairment.